Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 235
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Development of Novel Antifungal and Antimicrobial Small Compounds
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1155
Modern medicine is confronted by new and still unsolved challenges in its battle against pathogen born diseases. It is yet to find satisfactory answers to the sharp increase...
Email me a copy of this message

Modern medicine is confronted by new and still unsolved challenges in its battle against pathogen born diseases. It is yet to find satisfactory answers to the sharp increase in antibiotic resistant bacterial strains, a growing problem in developed countries, and still lacks appropriate solutions for combating fungal infections. The lack of suitable solutions requires adopting new approaches and finding new solutions in both fields. One of the approaches currently being tested exploits a broad spectrum of naturally occurring antimicrobial peptides, which are part of the innate immunity of all organisms. Their antimicrobial activity is attributed to their ability to disrupt the microorganism's membrane inducing cell lyses. Many fully lyse the target cell, which reduces the probability for new resistant strains to emerge. Although quite effective, these peptides have several drawbacks when considered for therapeutic uses. Since they are of peptidic nature all the limitations concerning peptides apply to them, such as high manufacturing costs, instability, short half-life, etc. In addition their activity against eukaryotic pathogens such as fungi and yeast is very limited.


We aim to develop novel antifungal and antimicrobial compounds.


A novel family of potent antimicrobial compounds has been developed. These compounds posses a broad range of antibacterial and anti fungal activity, also effective against resistant strains. The mode of action is through cell lysis, of stationary as well as dividing cells, hence the compounds are bactericidal. Since the mode of operation is through cell lysis, it reduces the likelihood of developing resistant strains. The structure of the molecules allows high versatility, which may create a broad range of molecules with unique properties. These molecules may differ in their molecular weight, which may be as low as ~ 400 dalton, their pH sensitivity, stability and other properties.


Researchers at the Weizmann Institute have taken an advantage of certain features of the antimicrobial peptides to develop a novel family of potent antimicrobial compounds, some of which have molecular weight as low as ~400 dalton. These compounds have unique properties not found in known antimicrobial peptides or conventional antibiotics.


The diversity in structure, spectrum of activity and cost of production will allow their application for many purposes including therapeutics, material disinfection and food preservation. Please enquire quoting reference no. 1155 regarding licensing or codvelopment partnerships.
Last Updated May 2015
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL


Opportunity Contact